Edwards Lifesciences Corporation (ETR:EWL)

Market Cap	43.37B
Revenue (ttm)	5.01B
Net Income (ttm)	1.17B
Shares Out	n/a
EPS (ttm)	1.99
PE Ratio	37.20
Forward PE	31.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Average Volume	92
Open	75.02
Previous Close	75.18
Day's Range	74.88 - 75.02
52-Week Range	59.30 - 76.02
Beta	n/a
RSI	66.24
Earnings Date	Feb 13, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD